Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Idexx Laboratories (IDXX – Research Report), Neurocrine (NBIX – Research Report) and Exelixis (EXEL – Research Report).
Idexx Laboratories (IDXX)
Piper Sandler analyst David Westenberg maintained a Hold rating on Idexx Laboratories today and set a price target of $600.00. The company’s shares closed last Wednesday at $572.31, close to its 52-week high of $579.68.
According to TipRanks.com, Westenberg is a 4-star analyst with an average return of
Idexx Laboratories has an analyst consensus of Moderate Buy, with a price target consensus of $619.00, an 8.8% upside from current levels. In a report issued on February 5, Bank of America Securities also reiterated a Hold rating on the stock with a $600.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Neurocrine (NBIX)
Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Neurocrine yesterday and set a price target of $154.00. The company’s shares closed last Wednesday at $136.29, close to its 52-week high of $143.35.
According to TipRanks.com, Kulkarni is a 4-star analyst with an average return of
Neurocrine has an analyst consensus of Moderate Buy, with a price target consensus of $145.44, a 7.7% upside from current levels. In a report issued on January 23, Barclays also maintained a Buy rating on the stock with a $150.00 price target.
Exelixis (EXEL)
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Exelixis, with a price target of $29.00. The company’s shares closed last Wednesday at $20.18.
According to TipRanks.com, Olson is a 5-star analyst with an average return of
Exelixis has an analyst consensus of Strong Buy, with a price target consensus of $26.50, a 25.7% upside from current levels. In a report issued on January 25, Jefferies also maintained a Buy rating on the stock with a $30.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IDXX:
- Idexx Laboratories price target raised to $620 from $600 at Morgan Stanley
- Idexx Laboratories price target raised to $570 from $525 at Stifel
- Idexx Laboratories price target raised to $655 from $605 at Barclays
- Early notable gainers among liquid option names on February 5th
- Idexx Laboratories sees 2024 EPS $10.84-$11.33, consensus $11.00
